[1] Miller AD. Delivery of RNAi therapeutics: work in progress. Expert Rev Med Devices. 2013;10(6):781-811. DOI:
10.1586/17434440.2013.855471[2] Zhang L, et al. DSPE-mPEG2000-Modified Podophyllotoxin Long-Circulating Liposomes for Targeted Delivery: Their Preparation, Characterization, and Evaluation. Curr Drug Deliv. 2025 Jan 2. DOI:
10.2174/0115672018356666241224052638[3] ZHANG J, LUO Y, ZHAO X, et al. Co-delivery of doxorubicin and the traditional Chinese medicine quercetin using biotin–PEG2000–DSPE modified liposomes for the treatment of multidrug resistant breast cancer[J]. RSC Advances, 2016, 114: 113173-113184. DOI:
10.1039/c6ra24173e[4] GULAM MUSTAFA HASAN. Inhibition of the Growth of Plasmodium falciparum in Culture by Stearylamine-Phosphatidylcholine Liposomes.[J]. Journal of Parasitology Research, 2011, 2011: 120462. DOI:
10.1155/2011/120462[5] SHAILENDRA SINGH RATHORE Prahlad C G. Effect of surface charge and density of distearylphosphatidylethanolamine-mPEG-2000 (DSPE-mPEG-2000) on the cytotoxicity of liposome-entrapped ricin: Effect of lysosomotropic agents[J]. International Journal of Pharmaceutics, 2008, 350 1: Pages 79-94. DOI:
10.1016/j.ijpharm.2007.08.032[6] FATEME HAGHIRALSADAT. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.[J]. Artificial Cells, Nanomedicine, and Biotechnology, 2018, 46 1: 169-177. DOI:
10.1080/21691401.2017.1304403